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Renin.angiotensin system in neonatal rats: Induction of a renal abnor.
mality in response to ACE inhibition or angiotensin II antagonism. In
experiments designed to analyze cardiovascular structure in response
to antihypertensive therapy with an ACE inhibitor, we decided to start
very early in life with the aim to prevent blood pressure increases and
the development of vascular structural changes. In these treated groups
of rats we unexpectedly observed that after they were weaned, their
water consumption and urine volume, respectively, increased substan-
tially. The present study was designed to determine if inhibition of the
renin-angiotensin system produced similar effects in different strains of
rats, and focused on characterizing the abnormal fluid balance occur-
ring as a consequence to neonatal treatment with ACE inhibitors or
angiotensin II blockers. Three-day-old Wistar Kyoto (WKY), Wistar
(WR) and spontaneously hypertensive rats (SHR) were given either
saline, enalapril, captopril, losartan and the AT2 blocker, PD123319, in
the same amount of volume for 20 days. Treatment was stopped and
rats were examined with regard to renal morphology at 4, 14 and 30
weeks of age. In addition, water consumption, urine volume, urine
electrolytes and osmolality were analyzed at 14 weeks of age, that is, 10
weeks off treatment. Early treatment with the ACE inhibitors, enalapril
and captopril, and the AT1 blocker, losartan, but not the AT2 blocker,
PD 123319, in the SHR and in the normotensive strains WKY and WR
produced persistent, irreversible histopathological renal abnormalities
in adult life, long after the rats had been taken off treatment. These
abnormalities consisted of mainly cortical tubulointerstitial inflamma-
tion, various degrees of papillary atrophy and pelvic dilation. These
structural renal abnormalities impaired the urine concentrating ability in
the treated animals, as evidenced by a reduced urine osmolality, and
caused increases in water consumption and diuresis. These results
suggest an important role for angiotensin II in the developing kidney
during the first postnatal weeks or even days in the development of
normal renal function, a situation that should be seriously considered in
clinical situations when any extended ACE inhibitor therapy in new-
borns is discussed.
Angiotensin converting enzyme (ACE) inhibitors have been
very effective in both reducing blood pressure and normalizing
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vascular structural changes in experimentally hypertensive rats
[1—3] as well as altering vascular structure in normotensive
animals [4]. Further, ACE inhibitors have been demonstrated to
have persistent effects on vascular structure and blood pressure
following treatment withdrawal in the spontaneously hyperten-
sive rat (SHR) [1—3, 5]. In the latter studies [2, 3, 5], enalapril
and ramipril, respectively, were given as monotherapy to both
young and adult SHR, and regardless of when therapy was
initiated, persistent "structural down-regulation" of heart and
blood vessels was still evident long after cessation of treatment.
In most studies, antihypertensive treatments in SHR were not
started until the age of four to five weeks, focusing more on
regression than on prevention of vascular changes.
A recent study by Adams, Bobik and Friberg [6] showed that
there is a marked vascular structure-based increase in resis-
tance even in two-week-old SHR compared with age- and body
weight-matched Wistar Kyoto (WKY) normotensive rats. In
studies aimed at preventing these very early structural changes
measured in the hind limb skeletal muscle vascular bed of these
neonatal SHR [6], a series of experiments in which an ACE
inhibitor was given to neonatal SHR and WKY was initiated.
After cessation of this early therapy, we observed, unexpect-
edly, a persistent and substantial increase in diuresis and
consequently in water consumption in the post-weaning period
[4]. Circumstantial evidence (vide infra) would attribute these
effects to ACE inhibition/Angiotensin II antagonism.
The renin-angiotensin system is widely acknowledged to play
an important role for blood pressure regulation and sodium and
water balance in adult life. Less studied, however, is the
functional role of the renin-angiotensin system during the fetal
and the newborn periods. A physiological significance for this
system has been proposed during maturation, but this influence
seems to be more powerful near end-gestation and postnatal
than in early gestation [7].
Enalapril has been shown to be fetotoxic when administered
in late gestation in the rabbit, whereas up to mid gestation no
effects on fetal wastage were observed [8]. Moreover, Schu-
biger, Flury and Nussberger [9] reported acute renal failure in a
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neonate exposed to ACE inhibition treatment during preg-
nancy. The background of this fetotoxicity and renal disorder is
not known, but could be related to ACE inhibitor-induced
changes in renal morphology with consequences for tubular
concentrating mechanisms. Thus, ACE inhibitor treatment dur-
ing these conditions may not necessarily be toxic per Se, but the
lack of angiotensin II (Ang II) receptor stimulation may induce
a "physiologic" toxicity, which may secondarily impair renal
function. In such a case, Ang II antagonism would result in
similar renal damage, since the AT1 receptor distribution is
identical in the fetus to that found in the adult animal, while AT2
receptors are abundant in the mesenchyme and no binding is
evident in the kidney [10]. Similarly, in a very recent study by
Tufro-McReddie et al [11], it was shown that kidney AT1
mRNA levels increased from end-gestation to the newborn
period and that renal AT1 mRNA shifted location during
maturation. Hence, there is clear cut evidence of existing Ang
II receptors, predominantly AT1 receptors, in the immature
kidney, thus constituting possible action of ACE inhibitors and
Ang II antagonists.
In the present study, we examined the effects of specific
interventions in the activities of the renal angiotensin system on
renal morphology, water consumption, urine volumes and
electrolytes in SHR and normotensive control rats. We used
two ACE inhibitors with different chemical properties: capto-
pnl and enalapril of various doses. In addition, to link the renal
pathophysiological effects to lack of Ang II receptor stimula-
tion, neonates were treated with losartan, an AT1 receptor
antagonist, and to elucidate the involvement of possible AT2
receptors within the kidney as a possible cause for the fluid
balance changes, the AT2 receptor blocker PD123319 was also
administered.
Methods
Animals
Several groups of male SHR, WKY and ordinary Wistar rats
were used. Rats from colonies bred at the Baker Medical
Research Institute (SHR stock originally supplied by Prof Y.
Yamori in 1986), ALAB Breeding Centre (SOdertälje, Sweden,
mothers with pups aged 2 days) and Mollegaards Breeding
Centre (Skensved, Denmark) were used. All rats were housed
in rooms in which temperature was controlled around 25°C and
a 12-hour light/dark cycle was maintained. Food and water were
supplied ad libitum. Pregnant rats were observed carefully at
end-gestation to determine the exact birth date for the pups. On
the second day after birth, the mother was carefully handled
and the pups were sexed; only males were subsequently in-
jected in order to obtain similar adult body weights to corre-
spond with the male groups that were examined for vascular
structure design. Intraperitoneal daily injections started on the
third day after birth. Body weights were obtained daily to give
the correct dosing.
Group 1. Male SHR and WKY from the Baker Institute
colony and WR from Mollegaard Breeding Centre, respec-
tively, were injected with either enalapril maleate (10 mg/kg) or
saline in standardized volumes of 10 p11g. Injections started at
the third day of age and continued until 22 days of age. These
groups were then analyzed for renal histology at approximately
four weeks of age by immersion fixation in 10% formaldehyde
solution.
Group 2. Litters of male SHR and WKY from the Baker
Institute colony were treated with enalapril according to the
same procedure as used for group 1, but were then left
untreated for 10 weeks. Body weight and water consumption
were followed weekly. At 14 weeks of age, kidneys were
weighed and extirpated for assessment of renal histology.
Group 3. In separate groups of male Wistar rats (ALAB), the
AT1 antagonist losartan (former DuP 753, DuPont-Merck,
Wilmington, Delaware, USA) was used. Here neonates were
injected i.p. with saline, 10 and 30 mg/kg of losartan and
enalapril 10 mg/kg, using the same volume of injectate as in the
other groups. Animals were given injections from day 3 until
day 22, and were then taken off therapy and left untreated until
14 weeks of age.
Group 4. Three-day-old male Wistar rats were given 10 mg/kg
of the AT2 antagonist PD123319 (Park-Davis, USA) i.p. for 19
days. The rats were then taken off therapy and left untreated for
10 weeks. Wistar rats receiving 10 mg/kg of losartan were
injected in parallel according to the same protocol.
Group 5. WKY rats from the Baker Institute colony were
treated with enalapril from day 3 until day 22, and were then left
untreated until 30 weeks of age, when kidneys were extirpated
and assessed histopathologically. Age-matched saline-injected
rats served as controls.
Group 6. WKY rats from the Baker Institute colony were also
given captopril in two concentrations: 20 and 40 mg/kg, respec-
tively. The volume of the injectate was unchanged compared
with the enalapril regimen. Kidneys were extirpated at 4(20 and
40 mg/kg) and 14 (20 mg/kg) weeks of age and subsequently
examined histopathologically.
Fluid balance measurements
Water consumption was measured in rats from group 2 by
means of weighing water bottles. In all other groups water
consumption and urine volume measurements were assessed by
means of metabolic cages. Rats were put in cages for at least
two occasions, each period consisting of three days. They had
free access to food and water. Values were then averaged for
every 24 hours. However, the first 24 hour measurements were
discarded. Urine was collected and frozen for subsequent
analyses of osmolality, sodium and potassium.
Renal histology—Semiquantitative measurements
The examined kidney specimens were immersion-fixed.
These were then imbedded in paraffin and sliced in a microtome
for subsequent assessment by light microscopy. Several differ-
ent histopathological features were determined: the degree of
papillary atrophy, dilation of renal pelvis, glomerular sclerosis
and tubulointerstitial (TI) inflammation. All kidneys were char-
acterized using semi-quantitative assessments and each of the
above-mentioned parameters were given a score on a graded
scale, which consisted of 0 (no evident abnormalities),
and +++. For calculation purposes, these symbols were
expressed as 1 and + = 2. The tubutointerstitial inflam-
mation consisted mainly of infiltration of lymphocytes in the
interstitium. In some kidneys infiltrate of granulocytes was also
present, and in such cases it was found around tubular cells. In
addition, granulocytes were also found to infiltrate the tubular
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Fig. 1. Body weights (g) of neonatal, male
Wistar Kyoto rats (WKY, A, open squares)
and spontaneously hypertensive rats (SHR, B,
open circles) (groups I and 2) during daily
intraperitoneal injections of enalapril 10 mgI
kg (N = 19 for WKYandN 28 for SHR,
dotted lines) and saline (N = 14 for WKY and
N = 18 for SHR, solid lines). Note the notch
in the body growth curve at day 13 of age for
both SHR and WKY. From day 14 in both
treated groups body weight is significantly
____________________________
reduced vs. saline control (F 49, P <
0.0001, ANOVA). Solid lines indicate saline
treatment and dotted lines indicate enalapril
treatment. Data are mean SE. '' P < 0.001
versus respective saline group.
Fig. 2. Body weight (g) curves from 4 to 14
weeks of age in early treated (N = 12for
WKY,AandN= 12 for SHR,B) WKYand
their respective control, (solid lines) saline
group (N = 14 for WKYandN = l7for
SHR) (group 2). Both WKY and SHR treated
with enalapril (dotted lines) remained at a
lower body weight throughout the study
16 period (F = 178, P < 0.0001, ANOVA).
Symbols and lines as in Fig. 1. Data are mean
SEM.
epithelium. All histopathological assessments were coded and
were done by the researcher blind to the treatment.
Analyses of urine osmolality and electrolytes
Sodium and potassium samples of about 100 p.1 were mea-
sured in a flame spectrophotometer (FLM3, Radiometer,
Copenhagen, Denmark) and for measurements of osmolality (20
p.1 sample) the method of freezing point depression was used
(Wide Range Advanced Osmometer model 3M0, Advanced
Instruments Inc., Needham Heights, Massachusetts, USA).
Statistical evaluation
Three-way ANOVA and Bonferroni's post hoc test were
performed in testing for differences regarding body weights,
water intake, osmolality. Ii 4'lition, parametric (blood pres-
sure responses to angiote and non-parametric (renal
morphology) tests of paired and unpaired design were used.
Values are expressed as mean SEM. A P-value less than 0.05
was considered statistically significant.
Results
Body weights
Figure 1 shows the time course of increases in body weights
when neonatal rats were treated with enalapril (ANOVA for
treatment effect; F = 120). Enalapril treatment induced a
delayed effect on the growth of the WKY (Fig. 1A) which
became apparent about 13 days after initiating treatment when
the rats were aged between 14 and 16 days. Body weight,
although maintained, fell below those of the age-matched sa-
line-injected WKY (Fig. 1B). A similar effect was observed in
the neonatal SHR treated with enalapril. However, in this study
the effect on body weight was not as great as in WKY (Fig. 1B).
Figure 2 shows the time course of increases in body weights
from 4 to 14 weeks of age, that is, approximately from the
cessation of neonatal treatment and 10 weeks off treatment.
Due to the initial enalapril treatment a consistent reduction of
body weight persisted throughout the whole study period,
although it was not more than 9% (ANOVA for treatment
effect, F = 178, P < 0.0001). Body weight was reduced to a
similar degree in both WKY and SHR. Not only did treatment
with the ACE inhibitor enalapril cause retardation of body
weight, but also treatment with losartan resulted in a reduction
of the normal body weight gain in young and adult ages
compared with age-matched animals that received saline injec-
tions, similar to WKY (Figs. 1 and 2). Enalapril caused the most
marked effect, while the effect of losartan was moderate. In
addition, there was no difference in body weights when the
losartan dose was increased from 10 to 30 mg/kg. There was no
effect on body weight by PD123319 treatment.
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Fig. 3. Water consumption curves (mi/kg
body wt per 24 hr) from 4 to 14 weeks of age
in WKY (A) and SHR (B) (group 2) treated
neonataily with either enalapril (dotted lines)
or saline (solid lines). Symbols are as in Fig.
2; numbers of animals equal those given in
Fig. 2. Note the dramatic treatment effect of
enalapril in both groups (F = 1141, P <
0.0001, ANOVA). In addition, there is a
marked difference between treated SHR and
WKY, showing less effect of treatment in
StiR (F = 392, P < 0.0001). Mean SEM is
expressed in all data points.
Table 1. Fluid balance, sodium and potassium excretion and urine osmolality in male neonatally treated and untreated Wistar rats measured
at 14 weeks of age
Treatment N
Water intake Unne volume Na' excretion K" excretion .
Osmolahty
mOsm/kgmllkg/24 hr mmol/24 hr
Saline 5 106 12 46 7 1.97 0.05 2.65 0.19 922 185
Enalapril (10) 5 317 25 217 23 1.83 0.18 2.94 0.15 355 22
Losartan (10) 10 197 2o 126 13 2.07 0.14 2.83 0.14 522 49
Losartan (30) 6 250 23 184 21 2.12 0.14 3.14 0.14 486 54
PD123319 (10) 7 71 3 32 4 1.64 0.12 3.28 0.27 1674 138
Losartan (10) 6 174 ga 119 9 1.76 0.08 3.51 0.16 308 8o
Data are mean SE. Numbers in brackets represent dose in mg/kg.
a p < 0.001 between saline injected group and intervention groups and between the PD123319 and losartan, respectively
Table 2. Mean arterial pressure (MAP) responses following an acute
injection of 50 ng Ang i in 14-week-old Wistar rats (group 3) exposed
to neonatal treatment with either enalapril or saline
Treatment
MAP before MAP after Difference
SED Pzmm Hg
Saline
(N = 8)
Enalapril (10 mg/kg)(N=4)
113
107
142 29
132 25
4
3
0.001
0.001
Data are means. SED is standard error of the difference.
Fluid balance and electrolytes
Both WKY, WR and SHR exposed to early treatment with
enalapril and losartan respectively, showed a marked increase
in water consumption and urine volume from four weeks until
adult age, in spite of treatment withdrawal at four weeks of age
(Fig. 3, Table 1). SHR in this study seemed to be less sensitive
to the early therapy with enalapril with respect to water intake,
which was similar to the situation for body weight. Treatment
with PD1233 19 did not influence fluid balance at all; water
intake and urinary output were similar to control values (Table
1). Urine excretion of sodium and potassium remained unal-
tered in all treated groups compared with control groups (Table
1). Urine osmolality was normal in the PD 123319 treated group
compared with saline controls, while in enalapril and losartan
(10 and 30 mg/kg) treated animals, it was drastically reduced
(Table 1). This indicates that the urine concentration ability was
reduced markedly in rats that had been exposed to early
postnatal, short-term inhibition of ACE or to AT1 receptor
blockade, respectively.
Bloodpressure responses to angiotensin I
In group 3 rats receiving enalapril, the function of the RAS
was assessed in adult animals treated neonatally by means of
injecting Ang I and monitoring the MAP responses. Table 2
shows that these WR showed a similar rise in MAP, compared
with saline treated rats, with no significant difference between
groups, indicating at least a partially responsive renin-angioten-
sin system in the early enalapril-treated group.
Semiquantitative assessment of changes in renal histology
Rats that had been exposed neonatally to enalapril and
losartan showed gross renal histopathological changes at both 4
and 14 weeks of age compared with controls (Fig. 4, Table 3).
These consisted of tubulointerstitial (TI) chronic inflammation,
various degrees of papillary atrophy and renal pelvic dilation.
However, no kidneys showed any sign of glomerular sclerosis,
indicating absence of chronic renal disease affecting glomeruli.
In four-week-old neonatally treated SHR, WKY and WR, the
degree of TI inflammation as determined by semiquantitative
assessment was similar and less pronounced than at 14 weeks of
age (Fig. 5A). In similarly treated WKY and WR examined 10
weeks after treatment, the TI inflammation score had pro-
gressed significantly (Fig. SB), whereas it remained unaltered in
similarly treated 14-week-old SHR (Fig. 5). In group 5 early
treated WKY rats left untreated between 4 and 30 weeks of age,
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Fig. 4. Kidney sections, light microscopy (hematoxylin and eosin). A. WKY rat 14-weeks-old, control (magnification x 14). B. WR rat
4-weeks-old, enalapril treatment i.p. days 3 to 22. Note the papillary atrophy (magnification x 10.5). C. WKY rat 14-weeks-old, enalapril treatment
days 3 to 22. The papillary atrophy and the tubulointerstitial inflammation are more pronounced than in B (magnification X 18). D. Higher
magnification of marked area in C. Arrows show clusters of inflammatory cells in the tubulointerstitial tissue (magnification x 70).
the TI inflammation score further increased compared with the showed total lack of any pathological changes. Furthermore, a
score at 14 weeks of age (from 6.50 0.65 to 8.33 2.02, P < clear dose-dependent effect on TI inflammation score was evident
0.05, respectively). Thirty-week-old saline injected controls in the groups receiving losartan 10 and 30 mg/kg (Fig. SB).
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Group rats treatment N Age
Papillary
atrophy
score
Pelvic
dilation
score
l.WKY+SHR-saline 6 4 0 0
l.WKY+SHR-enalapril 4C 4 0 0
l.WR-enalapril 10 mg/kg 20 4 2.10 0.40a 3.60 0.4o
2.WKY+SHR-saline 11 14 0 0
2.SHR-enalapril 10mg/kg 4 14 1.75 0.48a 0.75 0.48a
2.WKY-enalapril 10 mg/kg 6 14 2.00 o.ooa 3.00 0.73a
3,WR-saline 10 14 0 0.80 0.61
3.WR-enalapril 10 mg/kg 5 14 4.80 0.37 2.80 0.97
3.WR-losartan 10 mg/kg 10 14 2.60 0.54 3.10 0.82
3.WR-losartan 30 mg/kg 6 14 5.00 0.82 0
4,WR-PD123319 10 mg/kg
4.WR-losartan 10 mg/kg
7
6
14
14
0
3.33 0,45b
0.43 0.20
3.50 070b
4.WR-saline 8 14 0 0
5.WKY-saline 7 30 0 0
6.WKY-enalapril 10 mg/kg 5 30 2,40 o.4o 0
A separate group of WKY (group 6) was given captopril
neonatally. The renal histological examination revealed similar
pathological changes as were induced by enalapril (compare to
Fig. 4). Similar to the losartan groups, a dose-dependent effect
with respect to TI inflammation score at four weeks of age could
be observed (20 and 40 mg/kg of captopril, respectively, Fig. 6).
One subgroup of WKY on early therapy with captopril (20
mg/kg) were left untreated from 4 to 14 weeks of age and the TI
inflammation score progressed significantly compared with that
obtained at four weeks of age (from 2.75 0.25 to 8.00 0.71,
P <0.001; Fig. 6).
A positive relationship was found between renal structure
and function which is evident in Figure 7. It shows a significant
correlation between TI score, that is, the degree of tubulointer-
stitial chronic inflammation and water intake, demonstrating the
importance of intact renal morphology for maintaining a normal
tubular concentrating ability.
A statistically significant degree of papillary atrophy was
already evident at four weeks of age in early enalapril-treated
WR, which also became evident in 14-week-old SHR and WKY
(Table 3). None of the saline groups showed any sign of
papillary atrophy. Similarly, both losartan regimens (10 and 30
mg/kg) caused papillary atrophy in a dose-dependent pattern.
PD123319 treated animals showed no evidence of altered renal
morphology or fluid balance (Table 3). Furthermore, we were
not able to detect any sign of pelvic dilation in our limited
number of saline-injected control rats, although this has been
reported in Wistar rats [12, 13]. In the treated groups, the pelvic
dilation score mimicked the pattern for papillary atrophy score,
with the exception of the 30-week-old early enalapril-treated
WKY, which for some reason showed papillary atrophy with-
out concomitant pelvic dilation (Table 3).
Discussion
The main findings of the present study with respect to effects
on renal structure and function following treatment of postnatal
rats with either captopril/enalapril or losartan were: (i) reduced
urine osmolality; (ii) increased urine production and conse-
quently increased water consumption; (iii) gross morphological
changes in the kidney. Normal fluid balance and normal renal
morphology were, however, seen in animals treated with the
AT2 receptor antagonist PD123319. All treated groups showed
normal urinary excretion of sodium and potassium. The alter-
ations of fluid balance in the ACE inhibitor losartan treated
groups were associated with marked cortical TI chronic inflam-
mation but also to papillary atrophy and pelvic dilatation.
Interestingly, urine volume and water intake were less affected
by enalapril treatment in SHR at 14 weeks of age compared with
similarly treated WKY, and accordingly the renal histopatho-
logical changes were less pronounced. A progression of the
histopathological changes were noted between 4 and 14 weeks
of age in WKY, which was even further exaggerated between 14
and 30 weeks of age, whereas no progression was evident in 14-
week-old SHR versus 4-week-old SHR. These findings indicate
that an intact renin-angiotensin system is needed in early life for
development of a normal tubular concentrating ability. This
effect seems to be specifically related to a lack of stimulation by
renal AT1 receptors.
Renal AT1 receptors, determined either by receptor binding
assay or gene expression, have been demonstrated in newborn
rats which showed the same pattern as in adult rats [9, 10].
Evidence for the presence of AT1 receptors has been presented
in glomeruli, proximal tubule, and inner stripe of the outer
medulla [14]. However, recent data by Zhuo et al [151, using
high resolution light and electron microscopic autoradiography,
demonstrated that type 1 interstitial cells located in the inner
stripe of the outer medulla are the primary sites for Ang II
receptors. A lack of AT1 receptor stimulation may, by disturb-
ing the intrarenal Ang II levels and the subsequent interaction
with type 1 interstitial cells, lead to an altered medullary
microcirculation and/or tubular function.
The significance of the renin-angiotensin system during the
late fetal stage and in the newborn period has been recognized
[7, 16]. It is therefore tempting to speculate that the lack of
stimulation of Ang II receptors at this early time in life leads to
tubular inflammation, which subsequently spreads to the inter-
stitium, and finally creates papillary atrophy and pelvic dilation.
Regardless of the mechanism, it is clear that the presence of
local/circulating Ang II during early development is critical for
maintenance of renal functional and structural integrity.
It is reasonable to believe that the neonatal treatment-
induced renal damage was not due to a completely non-
functioning renin-angiotensin system in adult age, since injec-
tion of a small dose of Ang I resulted in marked pressure
elevation. The pressure response to Ang I did not differ from
saline-injected controls. Thus, in all likelihood, the tissue ACE
should also be preserved, which favors the hypothesis that the
renal damage secondarily caused the fluid balance changes. One
could argue, however, that the early treatment with enalapril/
captopril caused irreversible CNS changes within the regions
Table 3. Semiquantative measurements of papillary atrophy and
pelvic dilation in treated and untreated spontaneously hypertensive
rats (STIR) and normotensive Wistar Kyoto rats (WKY) and ordinary
Wistar rats (WR) of 4, 14 and 30 weeks of age
Data are mean SE. The different groups are described in detail
under Methods.
a Statistical significant difference, P < 0.001
b Statistical significant difference (P < 0.001) between losartan in
group 4 and the other two groups in group 4
Several specimens were not possible to analyze due to autolysis
A 4 week-old B 14 week-old
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Fig. 5. Chronic tubulointerstitial
inflammation (TI score, arbitrary units) in 4-
(A, group 1) and 14-(B, groups 2 and 3)-week-
old WR, WKY and SHR treated neonatally
with saline (S), enalapril 10 mg/kg (E),
losartan 10 (L10) and 30 mg/kg (L30). There
was a clearcut progression of TI score during
the 10 week treatment free interval. In
addition, a dose-dependent effect on TI score
was seen with losartan therapy. * P < 0.001
from saline-injected rats, ** P < 0.01.
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Fig. 6. Chronic tubulointerstitial inflammation (TI score) in 4 and 14-
week-old WKY rats exposed to neonatal treatment with either saline or
20 and 40 mg/kg captopril, respectively (group 6). As with losartan 10
and 30 mg/kg treatment, also captopril demonstrated more renal dam-
age with increasing dose. * P < 0.001 from saline-injected controls,
**p < 0.01.
governing thirst and salt appetite. This explanation is less likely
since enalapril does not inhibit brain ACE in SHR following oral
administration [17]. In addition, Brattleboro rats born with
diabetes insipidus and a central polydipsia demonstrate a totally
normal renal medullary morphology [18]. Taken together, the
findings from these latter studies argue against any CNS-
induced changes in fluid balance, and support the concept that
the observed renal damage per se hampers tubular concentrat-
ing mechanisms.
Chronic interstitial inflammation has also been reported in
other instances associated with potential impairment of the
renin-angiotensin system. For example, chronic interstitial in-
flammation has been observed in marmosets and SHR and
WKY which were actively immunized against renin [19, 201.
These studies, in contrast to the present one, began their
therapy in older animals and the authors demonstrated immu-
noglobulins, mononuclear cell infiltration and fibrosis around
Fig. 7. Linear regression between TI score and water consumption in
neonatally enalapril and saline treated Wistar rats. Water consumption
was measured in metabolic cages at 14 weeks of age. Shortly thereafter
the rats were sacrificed and renal morphology was assessed semiquan-
titatively. Dotted lines indicate 95% confidence interval of the absolute
TI score value. r = 0.828 (F = 142, P < 0.0001, ANOVA).
the juxtaglomerular apparatus, while in the present study gb-
meruli and the juxtaglomerular apparatus were morphologically
unchanged.
It can be speculated that during the first two weeks of ACE
inhibitor treatment or AT1 antagonism the kidney damage is
likely to occur, since no kidney pathology was reported in adult
SHR and WKY by, for example, Harrap and co-workers [3],
who initiated ACE inhibitor therapy at two weeks of age, and
Lee et al [21], who gave captopril to the mothers during both
pregnancy and lactation. In the latter study it may be that very
little drug was delivered to the pups via the placenta and breast
milk, respectively. Those factors may interfere with the inter-
pretation of study results, at least with regard to effective drug
concentration in the pups during fetal and early postnatal
periods. In our group we were not able to demonstrate any renal
abnormalities in four-week-old rats that received enalapril via
breast feeding despite the very high dose of 100 mg/kg enalapril
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in drinking water to their mothers (Friberg and Adams, unpub-
lished observation), suggesting that the effective dose in the
neonate was not high enough to cause renal histopathological
changes.
Already at four weeks of age there was clear papillary
atrophy and signs of renal pelvic dilation in WR, which did not
further progress to 14 weeks of age (Table 3). In contrast to TI
inflammation score, we did not observe any progression of
papillary atrophy or pelvic dilation scores in 30-week-old
WKY. In the context of pelvic dilation (hydronephrosis) in rats,
one should bear in mind that this phenomenon occurs sponta-
neously (in approximately 2% [12]), with secondary physiolog-
ical consequences for renal hemodynamics and function [13].
At present we have examined a vast number of kidneys
morphologically, and among them many control rat kidneys of
various strains, and we have not been able to detect any sign of
spontaneous, congenital hydronephrosis. This suggests that the
various degree of pelvic dilatation and the associated TI inflam-
mation observed in the present study was specifically linked to
ACE inhibitor/AT1 antagonism therapy.
In summary, we have observed that early treatment with
ACE inhibitors (enalapril/captopril) and the AT1 blocker losar-
tan, but not the AT2 blocker PD123319, in SHR and in normo-
tensive strains WKY and WR produces persistent, irreversible
histopathological renal abnormalities in adult life long after the
rats have been taken off treatment, mainly consisting of cortical
tubulointerstitial inflammation, various degrees of papillary
atrophy and pelvic dilation. These structural renal abnormali-
ties impaired the urine concentrating ability in the treated
animals, as evidenced by a reduced urine osmolality, and
caused marked diuresis and thirst. These results suggest an
important role for intrarenal and/or circulating angiotensin II
actions within the kidney during the first postnatal weeks or
even days, in the development of normal renal function, and
they should be considered in clinical situations when any
extended ACE inhibitor therapy in newborns is discussed.
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